TWI622595B - 充當抗癌劑的經取代核苷衍生物 - Google Patents
充當抗癌劑的經取代核苷衍生物 Download PDFInfo
- Publication number
- TWI622595B TWI622595B TW105104968A TW105104968A TWI622595B TW I622595 B TWI622595 B TW I622595B TW 105104968 A TW105104968 A TW 105104968A TW 105104968 A TW105104968 A TW 105104968A TW I622595 B TWI622595 B TW I622595B
- Authority
- TW
- Taiwan
- Prior art keywords
- cancer
- mmol
- compound
- methyl
- etoac
- Prior art date
Links
- AQGOZRKFBKEVFZ-ZHALLVOQSA-N CCOCc1n[nH]c(C[C@H]([C@H]([C@H]([n]2c3ncnc(C)c3cc2)[O]=C=C)O)O)c1 Chemical compound CCOCc1n[nH]c(C[C@H]([C@H]([C@H]([n]2c3ncnc(C)c3cc2)[O]=C=C)O)O)c1 AQGOZRKFBKEVFZ-ZHALLVOQSA-N 0.000 description 1
- DJUZHNZMVHIRPJ-ZGAAAFHUSA-N C[C@@H]([C@H]([C@H]([C@H]1O)O)O[C@H]1[n]1c(ncnc2N)c2nc1)O Chemical compound C[C@@H]([C@H]([C@H]([C@H]1O)O)O[C@H]1[n]1c(ncnc2N)c2nc1)O DJUZHNZMVHIRPJ-ZGAAAFHUSA-N 0.000 description 1
- ZBUYPOCFIPAVOZ-WXXHYUIPSA-N C[C@H]([C@H]([C@H]([C@H]([n]1c2ncnc(C)c2cc1)O)O)O)[C@H](c1ccccc1)O Chemical compound C[C@H]([C@H]([C@H]([C@H]([n]1c2ncnc(C)c2cc1)O)O)O)[C@H](c1ccccc1)O ZBUYPOCFIPAVOZ-WXXHYUIPSA-N 0.000 description 1
- DJUZHNZMVHIRPJ-RWONEVQGSA-N C[C@H]([C@H]([C@H]([C@H]1O)O)O[C@H]1[n]1c2ncnc(N)c2nc1)O Chemical compound C[C@H]([C@H]([C@H]([C@H]1O)O)O[C@H]1[n]1c2ncnc(N)c2nc1)O DJUZHNZMVHIRPJ-RWONEVQGSA-N 0.000 description 1
- GNLMRHGPHSVOJQ-QSJFSLAZSA-N Cc1c(cc[n]2[C@@H]([C@@H]([C@@H]3O)O)O[C@@H]3C(c(cc3)ccc3F)(F)F)c2ncn1 Chemical compound Cc1c(cc[n]2[C@@H]([C@@H]([C@@H]3O)O)O[C@@H]3C(c(cc3)ccc3F)(F)F)c2ncn1 GNLMRHGPHSVOJQ-QSJFSLAZSA-N 0.000 description 1
- VVNQYJYZOIRSRC-HLNWXESRSA-N Cc1c(cc[n]2[C@@H]([C@@H]([C@@H]3O)O)O[C@H]3c(cc3)n[n]3-c3ccccc3)c2ncn1 Chemical compound Cc1c(cc[n]2[C@@H]([C@@H]([C@@H]3O)O)O[C@H]3c(cc3)n[n]3-c3ccccc3)c2ncn1 VVNQYJYZOIRSRC-HLNWXESRSA-N 0.000 description 1
- XREICMJCVZYTAR-CGKSDVGLSA-N Cc1c(cc[n]2[C@@H]([C@@H]3O)OC(C(c4cc(F)cc(C(F)(F)F)c4)O)[C@H]3O)c2ncn1 Chemical compound Cc1c(cc[n]2[C@@H]([C@@H]3O)OC(C(c4cc(F)cc(C(F)(F)F)c4)O)[C@H]3O)c2ncn1 XREICMJCVZYTAR-CGKSDVGLSA-N 0.000 description 1
- RASMCBDASZAHRP-RIUYPTKQSA-N Cc1c(cc[n]2[C@@H]([C@@H]3O)O[C@@H]([C@@H](c(cc4)ccc4F)O)[C@H]3O)c2ncn1 Chemical compound Cc1c(cc[n]2[C@@H]([C@@H]3O)O[C@@H]([C@@H](c(cc4)ccc4F)O)[C@H]3O)c2ncn1 RASMCBDASZAHRP-RIUYPTKQSA-N 0.000 description 1
- CJOLNWSXRHCRGA-RIUYPTKQSA-N Cc1c(cc[n]2[C@@H]([C@@H]3O)O[C@@H]([C@@H](c4ccccc4)O)[C@H]3O)c2ncn1 Chemical compound Cc1c(cc[n]2[C@@H]([C@@H]3O)O[C@@H]([C@@H](c4ccccc4)O)[C@H]3O)c2ncn1 CJOLNWSXRHCRGA-RIUYPTKQSA-N 0.000 description 1
- RASMCBDASZAHRP-RNGZQALNSA-N Cc1c(cc[n]2[C@@H]([C@@H]3O)O[C@@H]([C@H](c(cc4)ccc4F)O)[C@H]3O)c2ncn1 Chemical compound Cc1c(cc[n]2[C@@H]([C@@H]3O)O[C@@H]([C@H](c(cc4)ccc4F)O)[C@H]3O)c2ncn1 RASMCBDASZAHRP-RNGZQALNSA-N 0.000 description 1
- JJSRCFYJJKHXSP-FSNPWBFUSA-N Cc1c(cc[n]2[C@@H]([C@@H]3O)O[C@H]([C@@H](c4cc(N(C)C)ncc4)O)[C@H]3O)c2ncn1 Chemical compound Cc1c(cc[n]2[C@@H]([C@@H]3O)O[C@H]([C@@H](c4cc(N(C)C)ncc4)O)[C@H]3O)c2ncn1 JJSRCFYJJKHXSP-FSNPWBFUSA-N 0.000 description 1
- DQMAAYMQZKAQJY-FSNPWBFUSA-N Cc1ncnc2c1cc[n]2[C@@H]([C@@H]1O)O[C@H]([C@@H](c(cc2)cc3c2[n](C(F)F)cn3)O)[C@H]1O Chemical compound Cc1ncnc2c1cc[n]2[C@@H]([C@@H]1O)O[C@H]([C@@H](c(cc2)cc3c2[n](C(F)F)cn3)O)[C@H]1O DQMAAYMQZKAQJY-FSNPWBFUSA-N 0.000 description 1
- LOOUVRBRGOENGZ-FSNPWBFUSA-N Cc1ncnc2c1cc[n]2[C@@H]([C@@H]1O)O[C@H]([C@@H](c(cc2)cc3c2nc[n]3C(F)F)O)[C@H]1O Chemical compound Cc1ncnc2c1cc[n]2[C@@H]([C@@H]1O)O[C@H]([C@@H](c(cc2)cc3c2nc[n]3C(F)F)O)[C@H]1O LOOUVRBRGOENGZ-FSNPWBFUSA-N 0.000 description 1
- WNGZPIOXKRMXPJ-ORDFZIBCSA-N Cc1ncnc2c1cc[n]2[C@@H]([C@@H]1O)O[C@H]([C@@H](c2cccc(C(F)(F)F)c2)O)[C@H]1O Chemical compound Cc1ncnc2c1cc[n]2[C@@H]([C@@H]1O)O[C@H]([C@@H](c2cccc(C(F)(F)F)c2)O)[C@H]1O WNGZPIOXKRMXPJ-ORDFZIBCSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562119932P | 2015-02-24 | 2015-02-24 | |
| US62/119,932 | 2015-02-24 | ||
| US201562213801P | 2015-09-03 | 2015-09-03 | |
| US62/213,801 | 2015-09-03 | ||
| US201662279209P | 2016-01-15 | 2016-01-15 | |
| US62/279,209 | 2016-01-15 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201643176A TW201643176A (zh) | 2016-12-16 |
| TWI622595B true TWI622595B (zh) | 2018-05-01 |
Family
ID=55451515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW105104968A TWI622595B (zh) | 2015-02-24 | 2016-02-19 | 充當抗癌劑的經取代核苷衍生物 |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US10428104B2 (https=) |
| EP (1) | EP3262057B1 (https=) |
| JP (1) | JP6584521B2 (https=) |
| KR (1) | KR20170119705A (https=) |
| CN (1) | CN107278205A (https=) |
| AU (2) | AU2016225133B2 (https=) |
| BR (1) | BR112017017396A2 (https=) |
| CA (1) | CA2921314A1 (https=) |
| CL (1) | CL2017002155A1 (https=) |
| CO (1) | CO2017008403A2 (https=) |
| CR (1) | CR20170384A (https=) |
| CU (1) | CU20170105A7 (https=) |
| DO (1) | DOP2017000195A (https=) |
| EA (1) | EA031895B1 (https=) |
| ES (1) | ES2792899T3 (https=) |
| GT (1) | GT201700189A (https=) |
| IL (1) | IL253637A0 (https=) |
| MX (1) | MX2017010844A (https=) |
| NI (1) | NI201700095A (https=) |
| PE (1) | PE20171449A1 (https=) |
| PH (1) | PH12017501413A1 (https=) |
| SG (1) | SG11201706050WA (https=) |
| SV (1) | SV2017005514A (https=) |
| TN (1) | TN2017000357A1 (https=) |
| TW (1) | TWI622595B (https=) |
| UA (1) | UA118315C2 (https=) |
| UY (1) | UY36564A (https=) |
| WO (1) | WO2016135582A1 (https=) |
| ZA (1) | ZA201705092B (https=) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR104326A1 (es) * | 2015-05-04 | 2017-07-12 | Lilly Co Eli | Compuestos nucleósidos 5-sustituidos |
| TWI870767B (zh) | 2015-08-26 | 2025-01-21 | 比利時商健生藥品公司 | 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物 |
| US10898504B2 (en) | 2016-03-10 | 2021-01-26 | Janssen Pharmaceutica Nv | Substituted nucleoside analogues for use as PRMT5 inhibitors |
| AU2017230658B2 (en) | 2016-03-10 | 2021-03-04 | Janssen Pharmaceutica Nv | Substituted nucleoside analogues for use as PRMT5 inhibitors |
| US12084462B2 (en) | 2016-09-14 | 2024-09-10 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-MLL interaction |
| CA3033020A1 (en) | 2016-09-14 | 2018-03-22 | Janssen Pharmaceutica Nv | Fused bicyclic inhibitors of menin-mll interaction |
| EP3512857B1 (en) | 2016-09-14 | 2021-02-24 | Janssen Pharmaceutica NV | Spiro bicyclic inhibitors of menin-mll interaction |
| TN2019000087A1 (en) | 2016-10-03 | 2020-07-15 | Janssen Pharmaceutica Nv | Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors |
| WO2018065365A1 (en) | 2016-10-03 | 2018-04-12 | Janssen Pharmaceutica Nv | Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors |
| CN110248946B (zh) | 2016-12-15 | 2023-05-23 | 詹森药业有限公司 | Menin-MLL相互作用的氮杂环庚烷抑制剂 |
| US11220524B2 (en) * | 2017-02-20 | 2022-01-11 | Prelude Therapeutics Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) |
| WO2018152501A1 (en) * | 2017-02-20 | 2018-08-23 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| TN2019000212A1 (en) | 2017-02-27 | 2021-01-07 | Janssen Pharmaceutica Nv | Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor |
| WO2018160855A1 (en) | 2017-03-01 | 2018-09-07 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| EP3939986A1 (en) | 2017-08-09 | 2022-01-19 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| WO2019084470A1 (en) * | 2017-10-26 | 2019-05-02 | Prelude Therapeutics, Incorporated | SELECTIVE INHIBITORS OF THE PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) |
| US11059850B2 (en) | 2017-12-08 | 2021-07-13 | Janssen Pharmaceutica Nv | Spirobicyclic analogues |
| SMT202200396T1 (it) | 2017-12-13 | 2022-11-18 | Lupin Ltd | Composti eterociclici biciclici sostituiti come inibitori di prmt5 |
| US11396517B1 (en) | 2017-12-20 | 2022-07-26 | Janssen Pharmaceutica Nv | Exo-aza spiro inhibitors of menin-MLL interaction |
| AU2019235912B2 (en) * | 2018-03-14 | 2024-03-21 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) |
| US10711007B2 (en) | 2018-03-14 | 2020-07-14 | Prelude Therapeutics Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) |
| GB201810092D0 (en) | 2018-06-20 | 2018-08-08 | Ctxt Pty Ltd | Compounds |
| US12552826B2 (en) | 2018-08-07 | 2026-02-17 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
| EP3924360A1 (en) * | 2019-02-13 | 2021-12-22 | Prelude Therapeutics, Incorporated | Selective inhibitor of protein arginine methyltransferase 5 (prmt5) |
| IL318073A (en) * | 2019-03-25 | 2025-02-01 | California Inst Of Techn | PRMT5 inhibitors and their uses |
| JP2022526604A (ja) | 2019-04-05 | 2022-05-25 | プレリュード・セラピューティクス・インコーポレイテッド | タンパク質アルギニンメチルトランスフェラーゼ５の選択的阻害剤 |
| TW202112375A (zh) | 2019-06-06 | 2021-04-01 | 比利時商健生藥品公司 | 使用ｐｒｍｔ５抑制劑治療癌症之方法 |
| HUE064493T2 (hu) | 2019-06-10 | 2024-03-28 | Lupin Ltd | PRMT5 inhibitorok |
| KR20220019766A (ko) | 2019-06-12 | 2022-02-17 | 얀센 파마슈티카 엔.브이. | 신규 스피로바이사이클릭 중간체 |
| DK4299135T3 (da) | 2019-06-18 | 2025-09-08 | Pfizer | Benzisoxazol-sulfonamid-derivater |
| WO2021055797A1 (en) * | 2019-09-18 | 2021-03-25 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| KR20220086628A (ko) | 2019-10-22 | 2022-06-23 | 루핀 리미티드 | Prmt5 저해제의 약학적 조합물 |
| EP4069698A1 (en) | 2019-12-03 | 2022-10-12 | Lupin Limited | Substituted nucleoside analogs as prmt5 inhibitors |
| TW202525813A (zh) | 2019-12-19 | 2025-07-01 | 比利時商健生藥品公司 | 經取代之直鏈螺環接衍生物 |
| PE20231743A1 (es) | 2020-08-18 | 2023-10-31 | Incyte Corp | Proceso e intermediarios para preparar un inhibidor de jak |
| IL300557A (en) | 2020-08-18 | 2023-04-01 | Incyte Corp | Process and intermediates for preparing a JAK1 inhibitor |
| WO2022074391A1 (en) * | 2020-10-08 | 2022-04-14 | Storm Therapeutics Limited | Compounds inhibitors of mettl3 |
| CN112679505B (zh) * | 2020-12-25 | 2022-04-22 | 杭州澳赛诺生物科技有限公司 | 一种4-甲基-7H-吡咯并[2,3-d]嘧啶的合成方法 |
| WO2022153161A1 (en) | 2021-01-14 | 2022-07-21 | Pfizer Inc. | Treatment of cancer using a prmt5 inhibitor |
| US12071439B2 (en) | 2021-07-12 | 2024-08-27 | Incyte Corporation | Process and intermediates for preparing a JAK inhibitor |
| US20250188110A1 (en) * | 2021-08-13 | 2025-06-12 | Albert-Ludwigs-Universität Freiburg | Specific small molecule inhibitors that block kmt9 methyltransferase activity and function |
| WO2024170488A1 (en) | 2023-02-13 | 2024-08-22 | Astrazeneca Ab | Prmt5 inhibitor for use in cancer therapy |
| WO2026008533A1 (en) | 2024-07-01 | 2026-01-08 | Janssen Pharmaceutica Nv | Prmt5 inhibitors for treating adenomas |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6492348B1 (en) * | 1998-06-23 | 2002-12-10 | Smithkline Beecham Corporation | Adenosine derivatives |
| US20040043960A1 (en) * | 2002-08-15 | 2004-03-04 | Jeff Zablocki | Partial and full agonists of A1 adenosine receptors |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5646128A (en) * | 1989-09-15 | 1997-07-08 | Gensia, Inc. | Methods for treating adenosine kinase related conditions |
| US5864033A (en) * | 1989-09-15 | 1999-01-26 | Metabasis Therapeutics, Inc. | Adenosine kinase inhibitors |
| US5795977A (en) * | 1989-09-15 | 1998-08-18 | Metabasis Therapeutics, Inc. | Water soluble adenosine kinase inhibitors |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035296A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Improved release of medicament active agents from a chewing gum coating |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| US6831069B2 (en) * | 1999-08-27 | 2004-12-14 | Ribapharm Inc. | Pyrrolo[2,3-d]pyrimidine nucleoside analogs |
| JP2012521359A (ja) * | 2009-03-20 | 2012-09-13 | アリオス バイオファーマ インク． | 置換されたヌクレオシドアナログおよびヌクレオチドアナログ |
| US20120077814A1 (en) | 2010-09-10 | 2012-03-29 | Zhong Wang | Sulfonamide, sulfamate, and sulfamothioate derivatives |
| WO2013009735A1 (en) * | 2011-07-13 | 2013-01-17 | Merck Sharp & Dohme Corp. | 5'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| WO2013044030A1 (en) * | 2011-09-23 | 2013-03-28 | Enanta Pharmaceuticals, Inc. | 2'-chloroacetylenyl substituted nucleoside derivatives |
| US20170198006A1 (en) * | 2014-06-25 | 2017-07-13 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| AR104326A1 (es) * | 2015-05-04 | 2017-07-12 | Lilly Co Eli | Compuestos nucleósidos 5-sustituidos |
| AU2016301188A1 (en) * | 2015-08-06 | 2018-02-15 | Chimerix, Inc. | Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents |
-
2016
- 2016-02-15 MX MX2017010844A patent/MX2017010844A/es unknown
- 2016-02-15 EA EA201791563A patent/EA031895B1/ru not_active IP Right Cessation
- 2016-02-15 PE PE2017001447A patent/PE20171449A1/es unknown
- 2016-02-15 CU CUP2017000105A patent/CU20170105A7/xx unknown
- 2016-02-15 CN CN201680011823.1A patent/CN107278205A/zh active Pending
- 2016-02-15 JP JP2017544584A patent/JP6584521B2/ja not_active Expired - Fee Related
- 2016-02-15 AU AU2016225133A patent/AU2016225133B2/en not_active Ceased
- 2016-02-15 CR CR20170384A patent/CR20170384A/es unknown
- 2016-02-15 ES ES16707209T patent/ES2792899T3/es active Active
- 2016-02-15 WO PCT/IB2016/050803 patent/WO2016135582A1/en not_active Ceased
- 2016-02-15 BR BR112017017396A patent/BR112017017396A2/pt not_active Application Discontinuation
- 2016-02-15 KR KR1020177026762A patent/KR20170119705A/ko not_active Ceased
- 2016-02-15 UA UAA201708102A patent/UA118315C2/uk unknown
- 2016-02-15 SG SG11201706050WA patent/SG11201706050WA/en unknown
- 2016-02-15 EP EP16707209.9A patent/EP3262057B1/en active Active
- 2016-02-15 TN TNP/2017/000357A patent/TN2017000357A1/en unknown
- 2016-02-17 US US15/045,679 patent/US10428104B2/en active Active
- 2016-02-19 CA CA2921314A patent/CA2921314A1/en not_active Abandoned
- 2016-02-19 TW TW105104968A patent/TWI622595B/zh not_active IP Right Cessation
- 2016-02-22 UY UY0001036564A patent/UY36564A/es not_active Application Discontinuation
-
2017
- 2017-07-24 IL IL253637A patent/IL253637A0/en unknown
- 2017-07-26 ZA ZA2017/05092A patent/ZA201705092B/en unknown
- 2017-07-28 NI NI201700095A patent/NI201700095A/es unknown
- 2017-08-08 PH PH12017501413A patent/PH12017501413A1/en unknown
- 2017-08-14 SV SV2017005514A patent/SV2017005514A/es unknown
- 2017-08-17 CO CONC2017/0008403A patent/CO2017008403A2/es unknown
- 2017-08-21 DO DO2017000195A patent/DOP2017000195A/es unknown
- 2017-08-24 CL CL2017002155A patent/CL2017002155A1/es unknown
- 2017-08-24 GT GT201700189A patent/GT201700189A/es unknown
-
2018
- 2018-12-11 AU AU2018278842A patent/AU2018278842A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6492348B1 (en) * | 1998-06-23 | 2002-12-10 | Smithkline Beecham Corporation | Adenosine derivatives |
| US20040043960A1 (en) * | 2002-08-15 | 2004-03-04 | Jeff Zablocki | Partial and full agonists of A1 adenosine receptors |
Non-Patent Citations (6)
| Title |
|---|
| Kanchan Devkota et al., Analogues of the Natural Product Sinefungin as Inhibitors of EHMT1 and EHMT2, ACS Medicinal chemistry letters, vol.5, 2014, pp.293-297 |
| Kung PP et al., Design, synthesis, and biological evaluation of novel human 5'-deoxy-5'-methylthioadenosine phosphorylase (MTAP) substrates, Bioorganic & Medicinal Chemistry Letters, vol.15, 2005, pp.2829-2833 |
| Müller CE et al., Recent developments in adenosine receptor ligands and their potential as novel drugs, Biochim Biophys Acta, vol.1808, 2010, pp.1290-1308 |
| Müller CE et al., Recent developments in adenosine receptor ligands and their potential as novel drugs, Biochim Biophys Acta, vol.1808, 2010, pp.1290-1308 Kanchan Devkota et al., Analogues of the Natural Product Sinefungin as Inhibitors of EHMT1 and EHMT2, ACS Medicinal chemistry letters, vol.5, 2014, pp.293-297 Ritesh Kumar et al., Activation and inhibition of DNA methyltransferases by S-adenosyl-l-homocysteine analogues, Bioorganic & Medicinal Chemistry, vol.16, 2008, pp.2276-2285 Kung PP et al., Design, synthesis, and biological evaluation of novel human 5'-deoxy-5'-methylthioadenosine phosphorylase (MTAP) substrates, Bioorganic & Medicinal Chemistry Letters, vol.15, 2005, pp.2829-2833 Tilburg EW et al., 5'-O-alkyl ethers of N,2-substituted adenosine derivatives: partial agonists for the adenosine A1 and A3 receptors, J. Med. Chem., vol.44, 2001, pp.2966-2975 * |
| Ritesh Kumar et al., Activation and inhibition of DNA methyltransferases by S-adenosyl-l-homocysteine analogues, Bioorganic & Medicinal Chemistry, vol.16, 2008, pp.2276-2285 |
| Tilburg EW et al., 5'-O-alkyl ethers of N,2-substituted adenosine derivatives: partial agonists for the adenosine A1 and A3 receptors, J. Med. Chem., vol.44, 2001, pp.2966-2975 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI622595B (zh) | 充當抗癌劑的經取代核苷衍生物 | |
| CN109890797B (zh) | 可用作抗癌剂的取代的碳核苷衍生物 | |
| EP4667458A1 (en) | Pharmaceutical composition for treatment of cancer, comprising sos1 inhibitor and anticancer drug | |
| JP2021512131A (ja) | 抗ガン剤として有用な置換キナゾリン誘導体と置換ピリドピリミジン誘導体 | |
| TWI672304B (zh) | 作爲酪胺酸激酶抑制劑之經取代的乙炔基雜雙環化合物 | |
| EA034119B1 (ru) | Гетероарильные соединения, пригодные в качестве ингибиторов sumo-активирующего фермента | |
| CN104854108A (zh) | 作为pi3k抑制剂的吡咯并三嗪酮 | |
| TW200526639A (en) | Pyrazole derivatives and uses thereof | |
| EP3632443A1 (en) | Anti-tumor effect potentiator using novel biphenyl compound | |
| TW202110848A (zh) | 取代的稠合雙環類衍生物、其製備方法及其在醫藥上的應用 | |
| CN108191837A (zh) | PI3Kα/mTOR双激酶抑制剂及其药物组合物和应用 | |
| KR102386403B1 (ko) | 신규한 디옥솔로이소퀴놀린온 유도체 화합물 및 이의 용도 | |
| WO2021197467A1 (zh) | 多靶点的抗肿瘤化合物及其制备方法和应用 | |
| HK1241886A1 (en) | Substituted nucleoside derivatives useful as anticancer agents | |
| OA18433A (en) | Substituted nucleoside derivatives useful as anticancer agents | |
| WO2016204135A1 (ja) | ５員ヘテロ環誘導体 | |
| TW202128707A (zh) | 稠合四環類衍生物、其製備方法及其在醫藥上的應用 | |
| HK40008995A (en) | Substituted carbonucleoside derivatives useful as anticancer agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |